Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 16/20 | 0.65 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18198054 | 0.94 | NR1H4 (0.61) | NR1H4MAPTPOLBTP53 | |
| SCHEMBL18198085 | 0.93 | NR1H4 (0.62) | NR1H4MAPTPOLBTP53 | |
| SCHEMBL16702182 | 0.91 | NR1H4 (0.62) | NR1H4MAPTPOLBTP53 | |
| SCHEMBL18198058 | 0.91 | NR1H4 (0.64) | NR1H4MAPTPOLBTP53 | |
| SCHEMBL16702203 | 0.90 | NR1H4 (0.67) | NR1H4MAPTPOLB | |
| SCHEMBL21574217 | 0.90 | NR1H4 (0.63) | NR1H4MAPTPOLBTP53 | |
| SCHEMBL18191629 | 0.90 | NR1H4 (0.67) | NR1H4MAPTPOLB | |
| SCHEMBL18191661 | 0.90 | NR1H4 (0.63) | NR1H4MAPTPOLBTP53 | |
| SCHEMBL18191574 | 0.89 | NR1H4 (0.60) | NR1H4MAPTPOLB | |
| SCHEMBL18191628 | 0.89 | NR1H4 (0.60) | NR1H4MAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210253534-A1 | COMPOSITIONS AND METHODS FOR MODULATING FARNESOID X RECEPTORS | CHINA NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH CO., LTD (CN) | 2021-08-19 | — | — | US | disclosed |
| US-20210253534-A1 | COMPOSITIONS AND METHODS FOR MODULATING FARNESOID X RECEPTORS | CHINA NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH CO., LTD (CN) | 2021-08-19 | — | — | US | disclosed |
| US-11021446-B2 | Compositions and methods for modulating farnesoid X receptors | NOVARTIS AG (CH) | 2021-06-01 | — | — | US | disclosed |
| US-11021446-B2 | Compositions and methods for modulating farnesoid X receptors | NOVARTIS AG (CH) | 2021-06-01 | — | — | US | disclosed |
| US-20200247757-A1 | COMPOSITIONS AND METHODS FOR MODULATING FARNESOID X RECEPTORS | NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC. | 2020-08-06 | — | — | US | disclosed |
| US-20200247757-A1 | COMPOSITIONS AND METHODS FOR MODULATING FARNESOID X RECEPTORS | NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC. | 2020-08-06 | — | — | US | disclosed |
| CN-107531721-B | Fused tricyclic pyrazole derivatives for modulating farnesoid X receptors | 诺华股份有限公司 | 2020-07-17 | — | — | CN | disclosed |
| US-10683271-B2 | Compositions and methods for modulating farnesoid X receptors | NOVARTIS AG (CH) | 2020-06-16 | — | — | US | disclosed |
| US-10683271-B2 | Compositions and methods for modulating farnesoid X receptors | NOVARTIS AG (CH) | 2020-06-16 | — | — | US | disclosed |
| EP-3288948-B1 | FUSED TRICYCLIC PYRAZOLE DERIVATIVES USEFUL FOR MODULATING FARNESOID X RECEPTORS | NOVARTIS AG (CH) | 2019-11-20 | — | — | EP | disclosed |
| US-9682939-B2 | Compositions and methods for modulating farnesoid X receptors | NOVARTIS AG (CH) | 2017-06-20 | — | — | US | disclosed |
| US-9682939-B2 | Compositions and methods for modulating farnesoid X receptors | NOVARTIS AG (CH) | 2017-06-20 | — | — | US | disclosed |
| US-20160340317-A1 | COMPOSITIONS AND METHODS FOR MODULATING FARNESOID X RECEPTORS | NOVARTIS AG (CH) | 2016-11-24 | — | — | US | disclosed |
| US-20160340317-A1 | COMPOSITIONS AND METHODS FOR MODULATING FARNESOID X RECEPTORS | NOVARTIS AG (CH) | 2016-11-24 | — | — | US | disclosed |
| US-20160340317-A1 | COMPOSITIONS AND METHODS FOR MODULATING FARNESOID X RECEPTORS | NOVARTIS AG (CH) | 2016-11-24 | — | — | US | disclosed |
| WO-2016174616-A1 | FUSED TRICYCLIC PYRAZOLE DERIVATIVES USEFUL FOR MODULATING FARNESOID X RECEPTORS | NOVARTIS AG (CH) | 2016-11-03 | — | — | WO | disclosed |
| WO-2016174616-A1 | FUSED TRICYCLIC PYRAZOLE DERIVATIVES USEFUL FOR MODULATING FARNESOID X RECEPTORS | NOVARTIS AG (CH) | 2016-11-03 | — | — | WO | disclosed |
| EP-3065738-A1 | COMPOSITIONS AND METHODS FOR MODULATING FARNESOID X RECEPTORS | NOVARTIS AG (CH) | 2016-09-14 | — | — | EP | disclosed |
| WO-2015069666-A1 | COMPOSITIONS AND METHODS FOR MODULATING FARNESOID X RECEPTORS | IRM LLC (BM) | 2015-05-14 | — | — | WO | disclosed |
| WO-2015069666-A1 | COMPOSITIONS AND METHODS FOR MODULATING FARNESOID X RECEPTORS | IRM LLC (BM) | 2015-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11021446-B2 | Compositions and methods for modulating farnesoid X receptors | NR1H4, GPBAR1, SLC10A1 | NR1H4 1/4885MAPT 4447/4885POLB 4852/4885 |
| US-20210253534-A1 | COMPOSITIONS AND METHODS FOR MODULATING FARNESOID X RECEPTORS | NR1H4, GPBAR1, SLC10A1 | NR1H4 1/4885MAPT 4447/4885POLB 4852/4885 |
| US-20200247757-A1 | COMPOSITIONS AND METHODS FOR MODULATING FARNESOID X RECEPTORS | NR1H4, GPBAR1, SLC10A1 | NR1H4 1/4885MAPT 4447/4885POLB 4852/4885 |
| US-20160340317-A1 | COMPOSITIONS AND METHODS FOR MODULATING FARNESOID X RECEPTORS | NR1H4, GPBAR1, SLC10A1 | NR1H4 1/4885MAPT 4447/4885POLB 4852/4885 |
| US-10683271-B2 | Compositions and methods for modulating farnesoid X receptors | NR1H4, GPBAR1, SLC10A1 | NR1H4 1/4885MAPT 4447/4885POLB 4852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.